Dr. Priyom Bose

Dr. Priyom Bose

Feature Writer

B.Sc. Botany, M.Sc. Plant Biology and Biotechnology, Ph.D. Plant Biology and Biotechnology

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Articles from Priyom

Effectiveness of copper nanoparticle-based spray coating against SARS-CoV-2

Effectiveness of copper nanoparticle-based spray coating against SARS-CoV-2

Investigating incidence and clinical features of post-acute sequelae of COVID-19 in children and adolescents

Investigating incidence and clinical features of post-acute sequelae of COVID-19 in children and adolescents

A 6.4 million genome analysis predicts dominant SARS-CoV-2 variants

A 6.4 million genome analysis predicts dominant SARS-CoV-2 variants

Study illustrates risk of Omicron infection in fully vaccinated individuals

Study illustrates risk of Omicron infection in fully vaccinated individuals

Largest study to date on long COVID identifies a broad list of diagnoses

Largest study to date on long COVID identifies a broad list of diagnoses

Factors affecting exercise during COVID-19 pandemic

Factors affecting exercise during COVID-19 pandemic

Readiness of the United States to combat known and unknown future infectious pathogens

Readiness of the United States to combat known and unknown future infectious pathogens

Investigation of long-COVID in children with immunodeficiency

Investigation of long-COVID in children with immunodeficiency

Important methodology for targeting conserved epitopes of SARS-CoV-2 and an immune-focused approach in pan-sarbeco and universal CoV vaccine design

Important methodology for targeting conserved epitopes of SARS-CoV-2 and an immune-focused approach in pan-sarbeco and universal CoV vaccine design

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

Study demonstrates that ATV006 is orally bioavailable and has potent efficacy against SARS-CoV-2

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.